

Obstetrics & Gynecology Science

Hee-Yeong Jung, et al. Pelvic organ prolapse and hormone

Supplementary Table 1. The incidence rates (case number/100,000 person-years) of POP according to variables

	Non-MHT	Tibolone	Combined estrogen plus progestin by the manufacturer	Other oral MHT	Transdermal estrogen
Total	16,856/11,636,358 (145)	2,233/2,363,931 (94)	1,251/1,545,247 (81)	693/561,318 (123)	26/17,444 (149)
Age at inclusion (yr)					
40-49	541/1,044,699 (52)	218/407,197 (54)	168/353,374 (48)	94/120,313 (78)	3/2,793 (107)
50-59	5,991/5,619,692 (107)	1,369/1,542,407 (89)	836/1,020,238 (82)	353/308,739 (114)	14/10,919 (128)
60-69	7,496/3,574,283 (210)	579/370,587 (156)	223/159,056 (140)	216/110,355 (196)	9/3,390 (265)
70~	2,828/1,397,685 (202)	67/43,740 (153)	24/12,580 (191)	30/21,911 (137)	0/341 (0)
BMI (kg/m ²)					
<18.5	231/210,334 (110)	29/39,906 (73)	7/30,174 (23)	9/8,904 (101)	0/429 (0)
18.5-22.9	4,893/3,899,513 (125)	720/941,424 (76)	441/689,039 (64)	229/204,838 (112)	3/6,742 (44)
23.0-24.9	4,537/3,044,017 (149)	679/654,476 (104)	381/416,383 (92)	191/156,163 (122)	13/4,594 (283)
25.0-29.9	6,170/3,794,054 (163)	723/648,394 (112)	377/369,196 (102)	238/168,457 (141)	7/5,091 (138)
≥30	664/487,897 (136)	62/58,009 (107)	37/30,129 (123)	18/17,857 (101)	3/407 (738)
SES					
Mid-high SES	16,125/11,178,811 (144)	2,154/2,284,589 (94)	1,221/1,508,557 (81)	670/545,824 (123)	26/16,903 (154)
Low SES	731/457,547 (160)	79/79,341 (100)	30/36,690 (82)	23/15,494 (148)	0/540 (0)
Region					
Urban area	4,842/3,422,643 (141)	743/751,163 (99)	459/531,658 (86)	243/189,558 (128)	16/7,811 (205)
Rural area	12,014/8,213,715 (146)	1,490/1,612,768 (92)	792/1,013,590 (78)	450/371,759 (121)	10/9,632 (104)
CCI					
0	10,862/7,637,568 (142)	1,448/1,606,142 (90)	851/1,094,414 (78)	454/385,508 (118)	17/10,994 (155)
1	3,538/2,278,340 (155)	481/461,330 (104)	243/279,667 (87)	146/105,233 (139)	6/3,429 (175)
≥2	2,456/1,720,450 (143)	304/296,459 (103)	157/171,166 (92)	93/70,576 (132)	3/3,021 (99)
Parity					
0 or not respond	3,491/2,310,499 (151)	401/408,790 (98)	213/223,406 (95)	158/125,257 (126)	5/3,886 (129)
1	508/634,765 (80)	108/193,856 (56)	76/151,431 (50)	32/36,676 (87)	2/1,410 (142)
2	9,755/7,064,330 (138)	1,455/1,532,911 (95)	848/1,048,718 (81)	417/337,575 (124)	16/10,440 (153)
≥3	3,102/1,626,765 (191)	269/228,374 (118)	114/121,692 (94)	86/61,810 (139)	3/1,708 (176)
Age at menarche (yr)					
<13	2,858/2,111,305 (135)	322/354,442 (91)	187/228,715 (82)	115/99,524 (116)	4/3,143 (127)
≥13	13,846/9,453,511 (146)	1,890/1,988,998 (95)	1,055/1,306,351 (81)	567/453,726 (125)	22/14,092 (156)
Age at menopause (yr)					
40-44	1,793/1,545,494 (116)	218/282,895 (77)	123/179,441 (69)	131/110,648 (118)	5/3,346 (149)
45-49	4,718/3,369,944 (140)	681/770,031 (88)	390/519,950 (75)	212/189,076 (112)	9/6,178 (146)
50-54	8,589/5,732,859 (150)	1,095/1,126,819 (97)	612/740,166 (83)	300/226,991 (132)	11/6,677 (165)
55~	1,756/988,061 (178)	239/184,185 (130)	126/105,690 (119)	50/34,603 (144)	1/1,242 (81)
Smoking					
Never	15,270/10,640,820 (144)	2,034/2,132,432 (95)	1,160/1,397,655 (83)	629/511,834 (123)	22/15,909 (138)
Past	113/108,603 (104)	29/38,168 (76)	13/26,771 (49)	9/7,035 (128)	0/280 (0)
Current	271/273,510 (99)	75/101,217 (74)	28/68,954 (41)	15/18,318 (82)	1/290 (345)

Supplementary Table 1. The incidence rates (case number/100,000 person-years) of POP according to variables (Continued)

	Non-MHT	Tibolone	Combined estrogen plus progestin by the manufacturer	Other oral MHT	Transdermal estrogen
Alcohol (times/week)					
None	14,176/9,459,346 (150)	1,807/1,782,490 (101)	1,006/1,146,017 (88)	566/443,698 (128)	20/13,978 (143)
~2	1,340/1,391,021 (96)	301/432,154 (70)	175/307,172 (57)	74/86,065 (86)	4/2,409 (166)
3-6	123/158,876 (77)	29/56,215 (52)	18/39,756 (45)	8/8,639 (93)	1/211 (473)
Daily	79/62,893 (126)	10/18,345 (55)	6/10,883 (55)	2/3,626 (55)	0/87 (0)
Physical exercise (times/week)					
None	10,624/7,135,119 (149)	1,283/1,340,685 (96)	710/885,037 (80)	392/321,564 (122)	11/8,725 (126)
1-2	2,277/1,869,045 (122)	376/441,754 (85)	238/297,285 (80)	123/102,055 (121)	8/3,631 (220)
3-4	1,271/1,039,309 (122)	221/267,599 (83)	129/179,134 (72)	71/60,248 (118)	3/2,419 (124)
5-6	424/340,631 (124)	81/86,469 (94)	47/58,547 (80)	24/18,531 (130)	1/713 (140)
Daily	1,153/705,558 (163)	178/150,831 (118)	81/83,551 (97)	46/39,157 (117)	1/1,137 (88)
The period from menopause to inclusion (yr)					
<5	3,875/4,459,197 (87)	1,010/1,353,663 (75)	693/1,034,112 (67)	245/260,595 (94)	7/7,903 (89)
5-9	3,621/2,532,700 (143)	579/552,195 (105)	305/314,738 (97)	177/144,625 (122)	8/4,789 (167)
10~	9,360/4,644,461 (202)	644/458,073 (141)	253/196,398 (129)	271/156,097 (174)	11/4,752 (231)

Data are expressed as the case/person-years (case/100,000 person-years).

POP, pelvic organ prolapse; MHT, menopausal hormone therapy; BMI, body mass index; SES, socioeconomic status; CCI, Charlson comorbidity index.